Generate Biomedicines Inc (GENB) FinancialsGENBGenerate Biomedicines Inc

Evaluating the bottom line, Generate Biomedicines Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1134.21%, while the net margin is -1065.17%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively GENB converts its operational activities into shareholder value.

In the context of the broader market, GENB competes directly with industry leaders such as IMCR and NVAX. With a market capitalization of $1.64B, it holds a significant position in the sector. When comparing efficiency, GENB's gross margin of 100.00% stands against IMCR's 99.06% and NVAX's 78.93%. Such benchmarking helps identify whether Generate Biomedicines Inc is trading at a premium or discount relative to its financial performance.

The company's revenue has declined significantly, with Q2 2026 revenue at $6.3 million, down from $10.1 million year-over-year. The net loss for Q2 2026 was $67.3 million, indicating ongoing financial struggles.